| S.No. | Patent/ Publication No. | Patent focus (compounds, compositions, or etc.) | Compounds/ Active ingredients in compositions | Function of the compounds | Disease/disorder to be treated | Admini startion (oral, injection, or etc.) | Dolcera summary |
| 1 | US 7098029B1 | Food and beverage products | Peptide (C-terminal growth hormone fragment) | Stimulates the activity of hormone-sensitive lipase, inhibits acetyl CoA carboxylase, reduce lipogenic activity, and stimulate lipolysis | Obesity | Oral | Food or beverage comprises a transgenic plant or parts, which comprise a nucleic acid molecule, the nucleic acid molecule encoding a C-terminal growth hormone fragment which has the ability to modulate lipid metabolism |
| 2 | US 6596742B1 | Pharmaceutical composition, and compounds | Substituted 3-phenyl-5-alkoxy -1,3,4-oxadiazol-2-ones | Inhibits hormone-sensitive lipase | Non-insulin-dependent diabetes mellitus, and diabetic syndrome | N/A | Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones to treat metabolic disorder, which shows inhibitory effect on hormone sensitive lipase |
| 3 | US2007 0010423A1 | Pharmaceutical composition | Balaglitazone and one or more other anti-diabetic compounds, anti-diabetic compound is selected from amongst insulin secretagogues, insulin sensitizers, potassium channel openers, glucagons antagonists, protein tyrosine phosphatase inhibitors, glucokinase activators, RXR agonists, hormone sensitive lipase inhibitors, glycogen synthase kinase-3 inhibitors, glycogen phosphorylase inhibitors, glucose uptake modulators and lipid lowering compounds | Inhibits hormone sensitive lipase (in case of hormone sensitive lipase inhibitors as anti-diabetic) | Treat type 2 diabetes, dyslipidemia, hyperglycemia, hyperinsulinemia, insulin resistance, obesity, cardiovascular complications, atherosclerosis, hypertension, impaired glucose tolerance, impaired fasting glucose level, increased plasma levels of free fatty acids, increased levels of plasma triglycerides, amd increased plasma levels of very low density lipoproteins (VLDL) | N/A | A pharmaceutical composition comprising balaglitazone and one or more other anti-diabetic compounds. The anti-diabetic compounds may be hormone sensitive lipase inhibitors. |
| 4 | US2006 0160819A1 | Pharmaceutical compositions and compounds | Substitued piperazine carbamates | Inhibits of hormone sensitive lipase | Insulin resistance, diabetes type 1, diabetes type 2, metabolic syndrome X, impaired glucose tolerance, hyperglycemia, dyslipidemia, obesity, atheroschlerosis, hypertension, abnormalities of lipoprotein metabolism | Oral, nasal, transdermal, pulmonal, or parenteral | Novel piperazine carabamates and their compositions to treat or prevent diseases related to hormone sensitive lipase. Piperazine carabamates inhibit hormone sensitive lipase activity |
| 5 | US2006 0148860A1 | Pharmaceutical compositions, and compounds | Substituted p-phenyl carbamates | Inhibits the lipolytic activity of hormone sensitive lipase against triacylglycerols, diacylglycerols, cholesterol acyl esters or steroid acyl esters | Insulin resistance, diabetes type 1, diabetes type 2, metabolic syndrome X, impaired glucose tolerance, hyperglycemia, dyslipidemia, obesity, atheroschlerosis, hypertension, abnormalities of lipoprotein metabolism | Oral, nasal, transdermal, pulmonal, or parenteral | Substituted p-phenyl carbamates to treat hormone sensitive lipase related diseases. Substituted p-phenyl carbamates decrease the activity of hormone sensitive lipase |
| 6 | US2006 0148799A1 | Pharmaceutical compositions, and compounds | Substituted p-phenyl carbamates | Inhibits hormone sensitive lipase | Insulin resistance, diabetes type 1, diabetes type 2, metabolic syndrome X, impaired glucose tolerance, hyperglycemia, dyslipidemia, obesity, atheroschlerosis, hypertension, abnormalities of lipoprotein metabolism | Oral, nasal, transdermal, pulmonal, or parenteral | Substituted p-phenyl carbamates to treat or prevent diseases related to hormone sensitive lipase by lowering the activity of the hormone sensitive lipase |
| 7 | US2005 0271755A1 | Botanical compositions | Coumarin derivatives: 6,7-dihydroxycoumarin (esculetin), and esculetin like compounds | Modulates biological activity of at least one enzyme among the group consisting of pancreatic lipase (PL), lipoprotein lipase (LPL), and hormone sensitive lipase (HSL) | Obesity, cardiovascular disease, and diabetes | N/A | Botanical compositions to control of lipid accumulation and metabolism in mammals thereby providing prevention or treatment of obesity, diabetes, and heart disease |
| 8 | US2005 0197348A1 | Pharmaceutical composition, and compounds | Indazole derivatives | Inhibits hormone sensitive lipase | Insulin resistance, diabetes mellitus, dyslipidemias, and metabolic syndrome | N/A | Indazole derivatives to treat or prevent disorders of fatty acid metabolism and glucose utilization disorders, which inhibit hormone sensitive lipase |